CHAPTERS
- 0:01 – 1:02
Catching up: beard talk, biological age, and Aubrey’s personal habits
Joe and Aubrey reconnect after nearly five years, joking about Aubrey’s beard and whether anti-aging work has made him younger. Aubrey shares that his biological age tests tend to read about a decade younger than his chronological age, while also admitting his lifestyle (sleep, drinking) isn’t exactly “optimized.”
- •Aubrey hasn’t gotten younger yet; progress requires fixing all major damage types
- •Biological age testing suggests Aubrey is ~10 years younger biologically than 57
- •Aubrey drinks daily (beers plus whiskey) and doesn’t prioritize sleep
- •Conversation frames the gap between personal health habits and longevity science
- 1:02 – 4:14
What causes aging? The “machine damage” model and why decline accelerates after midlife
Aubrey explains aging as cumulative damage from normal operation—like rust or sludge in a car—rather than a mysterious biological program. The body tolerates damage long enough to reproduce, but after that the accumulated damage increasingly overwhelms repair capacity, accelerating decline after ~40–50.
- •Aging = inevitable damage accumulation from basic physics of “running” a system
- •Evolution optimizes for reproduction, not indefinite maintenance
- •Functional declines stay subtle until midlife, then accelerate
- •Recovery from injury is only one of many declining capacities
- 4:14 – 10:19
Why Aubrey doesn’t sell lifestyle advice: luck, tradeoffs, and what his days look like
Asked how he mitigates aging personally, Aubrey says he’s a poor role model: he’s genetically fortunate and prioritizes pushing the field forward over self-optimization. He describes a travel-heavy life focused on outreach because the “front man” role can’t be delegated as easily as lab work.
- •Aubrey credits good baseline physiology more than disciplined habits
- •He views advocacy/education as a high-leverage, non-delegable task
- •Science execution can be delegated to strong hires; public communication can’t
- •His routine is irregular due to heavy travel and speaking commitments
- 10:19 – 12:57
Rejuvenation strategy: repair beats “running cleaner,” and SENS focuses on the hardest problems
Aubrey outlines the SENS approach: aging is addressed by periodically repairing damage rather than merely slowing its creation. He explains why SENS is structured as an independent charity funded by philanthropy, enabling high-risk research that conventional grants often avoid.
- •Maintaining biological age implies repair; if you can match damage, you can exceed it
- •Divide-and-conquer: all key damage categories must be addressed
- •SENS targets the toughest, least-funded damage types; others do the “easier” work
- •Grant systems incentivize safe, publication-friendly projects over bold engineering
- 12:57 – 16:42
What changed in the last five years: investors arrive and clinical translation begins
Aubrey says the core understanding of aging hasn’t dramatically changed, but the ecosystem has: private-sector interest surged. He points to therapies entering trials (like senolytics and certain stem-cell applications) and describes a rapidly growing network of aligned startups and investors.
- •Scientific argument for damage-repair is broadly accepted; public/market buy-in is new
- •Senolytics: drugs targeting senescent cells are in clinical trials
- •SENS increasingly spins projects into startups when investors can scale budgets quickly
- •The longevity sector now includes 100+ companies with overlapping goals
- 16:42 – 21:57
Stem cells in aging vs injuries: the Parkinson’s case study and why it’s different
Joe shares his own injury-repair experience with stem cells, and Aubrey distinguishes acute injury treatment from true age-related decline. Aubrey then explains Parkinson’s as a relatively clean example of cell loss: replacing dopaminergic neurons in the substantia nigra via targeted injection.
- •Acute injury stem-cell use differs from treating slow, systemic aging damage
- •Parkinson’s driven by loss of dopaminergic neurons in a specific brain region
- •Therapy concept: inject dopaminergic precursor cells directly into substantia nigra
- •Historical fetal-cell attempts were hit-or-miss, but successes were dramatic
- 21:57 – 26:38
How close are we? Trials, timelines, and why funding has been the bottleneck
Aubrey discusses current trial status (early phases) and then answers the big question: when do we get comprehensive rejuvenation? He frames predictions probabilistically—currently estimating ~17 years for a 50/50 chance—arguing funding used to slow progress more than scientific unknowns.
- •Parkinson’s trials are early-stage; multiple groups are pursuing them globally
- •Aubrey’s estimate: 17 years for a 50/50 shot at decisive, comprehensive therapies
- •His earlier estimate (25 years) has shortened as funding/investability improved
- •Public psychology and cultural denial of aging still obstruct urgency and resources
- 26:38 – 46:31
Debunking ‘anti-aging is bad’: disease semantics, dictators, and the “pro-aging trance”
They tackle common objections: immortal dictators, boredom, and claims that aging is “natural” or “good.” Aubrey argues much resistance is psychological denial, and he reframes aging as a medical problem rather than a single “disease,” emphasizing it requires ongoing repair—not a one-time cure.
- •Dictator objection is statistically trivial and historically inconsistent
- •Aubrey prefers “medical problem” over “disease” to avoid implying one-off cure
- •Many named diseases (e.g., Alzheimer’s) are better understood as components of aging
- •He describes public denial as a ‘pro-aging trance,’ reinforced by cultural narratives
- 46:31 – 55:13
Overpopulation and environment: why longer lives don’t automatically mean planetary collapse
Joe raises overpopulation concerns, and Aubrey argues the constraint is pollution and resource intensity, not literal space. He claims technological shifts—renewables, carbon capture, desalination, plastic-eating microbes, and especially cultured meat—will expand carrying capacity faster than population grows, while fertility rates trend downward.
- •Environmental strain is driven by per-capita pollution, especially carbon, not land area
- •Renewables already outcompete fossil fuels economically; carbon removal is advancing
- •Cultured meat could reduce land use and methane; similar logic could apply to fish
- •Fertility rates are declining globally; longer lifespans may further delay childbirth
- 55:13 – 1:11:21
Society after longevity: expectation shifts, pensions, healthcare, and automation collide
Aubrey argues the biggest near-term disruption isn’t 500-year-olds—it’s the moment people believe radical longevity is coming. He predicts a sudden change in public expectations (within a few years) that forces political commitments, economic redesign (pensions/insurance), and preparation for a world also reshaped by AI-driven job displacement.
- •Longevity is a side effect of health; the societal shock is ‘anticipation’
- •He forecasts a rapid, media-driven tipping point in public belief (3–5 years)
- •Healthcare savings are substantial, but indirect productivity gains may be larger
- •Automation may undermine full-employment economics; pensions/retirement logic must change
- 1:11:21 – 1:13:48
Toolbox for rejuvenation: senolytics, gene therapies, waste removal—and why mice matter
They return to the practical science: a comprehensive suite is needed (senolytics, stem cells, mitochondrial/DNA interventions, waste clearance). Aubrey explains what kind of animal proof would shift mainstream scientific messaging: big lifespan extension starting late in life (middle-aged mice), indicating true rejuvenation rather than lifelong ‘optimization.’
- •Different therapies target different damage categories; they complement rather than compete
- •Key milestone: extend lifespan substantially when treatment starts in middle age
- •Genetic interventions from birth are less persuasive for humans already alive
- •Reality check: combining multiple therapies will create interaction risks and delays
- 1:13:48 – 1:40:42
CRISPR, embryo editing controversy, medical tourism, and realistic lifestyle levers (fasting & stress)
Aubrey explains CRISPR as cheap, precise gene editing and discusses safety issues like off-target effects and limits (e.g., inserting large new genes). They address China’s embryo-editing scandal, the role and risks of offshore regenerative clinics, and then pivot to what individuals can do now—fasting for modest benefits, and stress resilience as a major longevity factor seen in centenarians.
- •CRISPR enables targeted gene edits; improvements are reducing off-target ‘vandalism’
- •Embryo CCR5 edits in China were ethically and technically controversial; intelligence claims are clickbait
- •Medical tourism can generate data but needs transparent outcomes and long-term follow-up
- •Fasting helps health but likely adds only modest longevity in humans; stress regulation appears strongly protective
